- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04939883
Effekter av karvedilol på kardiotoxicitet hos cancerpatienter som genomgår antracyklinterapi (CardioTox)
En prospektiv multicenter randomiserad studie för att utvärdera effekterna av karvedilol på kardiotoxicitet hos cancerpatienter som genomgår antracyklinterapi
Neoplasia is the main cause of general death in the Brazilian population. In 2016, they were responsible for approximately 211,343 (16%) deaths, followed by cardiovascular diseases (12.6%). Despite the high mortality rate of neoplasia, oncological treatment have advanced substantially in recent decades improving the prognosis of patients. However, growing evidence suggest that some oncological agents may induce significant toxicity that may play a major role in the quality of life, morbidity and mortality. The cardiovascular system is often negatively affected with cancer therapy, predisposing several patients to stop appropriate treatments or to have cardiovascular events related to the cardiotoxicity. The most typical manifestation of cardiotoxicity and related consequences (heart failure) are related to the use of anthracyclines. Anthracyclines are part of the chemotherapy regimen for solid tumors and hematological neoplasms in children and adults, and are associated with an increase in life expectancy. Carvedilol is an α and β-blocker that also has antioxidant properties. Preliminary studies have shown that carvedilol and its metabolites prevent lipid peroxidation, inhibit the formation and inactivate free radicals, in addition to preventing the depletion of endogenous antioxidants, such as vitamin E. These effects would potentially prevent anthracycline injury but definitive evidence is still needed. This is a multi-center, double-blind, randomized, placebo-controlled study that aims to establish the efficacy of carvedilol for the primary prevention of left ventricular systolic dysfunction in cancer patients obtained with anthracycline chemotherapy, in different schedules and doses.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 4
Kontakter och platser
Studieorter
-
-
São Paulo
-
São Paulo, São Paulo, Brasilien, 01308-050
- Hospital Sirio Libanes
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- ≥18 years of age at the time of screening
- Cancer patients that will receive chemotherapy with anthracyclines.
Exclusion Criteria:
- Inability to adequate asses left ventricular function
- Previous symptoms (dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and pulmonary and systemic congestion) suggestive of or a previous diagnosis of heart failure.
- Previous history of any cardiomyopathy (eg.: valve disease, Chagas' disease, infiltrative cardiomyopathy)
- LVEF < 50%
- Previous history of myocardial revascularization
- Permanent tachyarrhythmia (flutter, atrial fibrillation, atrial tachycardia)
- Congenital heart disease with left ventricular function impared
- Contra-indication to the use of beta-blockers.
- Pregnant or Breast-feeding females or women of childbearing age who intend to became pregnant.
- On kidney replacement therapy
- ECOG >= 4 or Karnofsky <=30
- Advanced hepatic failure (C score Child-Pugh and MELD > 15);
- Previous use of anthracycline
- Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study
- Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Förebyggande
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Intervention Group
Patients allocated to the intervention group will receive carvedilol 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily according to the patients' tolerance; The dosis increments will occur every 5 days. If after the increment the patient develops bradycardia or hypotension, the dose will be reduced to the maximum tolerated dose. Carvedilol will ideally be maintained for up to 30 days after the end of chemotherapy. |
Carvedilol will be dispensed in a staggered and progressive manner, initially from 6.25 mg twice daily, then increased to 12.5 mg twice daily, until maximum dose of 25 mg twice daily or development of contraindications |
|
Placebo-jämförare: Control Group
Patients allocated to this group will receive placebo in a presumably staggered and progressive manner similar to the group intervention. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
Patients will receive placebo in a presumed staggered and progressive manner similar to the intervention group. The placebo will ideally be maintained for up to 30 days after the end of chemotherapy. |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Drop in ejection fraction within 12 months of starting treatment.
Tidsram: 12 months
|
Drop in ejection fraction> 10% to values less than 50% of the left ventricle |
12 months
|
|
Cardiac events within 12 months of starting treatment.
Tidsram: 12 months
|
Cardiac events such as death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias |
12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Drop in ejection fraction within 12 months.
Tidsram: 12 months
|
Drop in ejection fraction greater than 10% and values less than 55% |
12 months
|
|
Reduction in myocardial strain in 12 months from the start of treatment.
Tidsram: 12 months
|
Relative reduction of more than 15% in myocardial strain |
12 months
|
|
Diastolic dysfunction within 12 months
Tidsram: 12 months
|
Development of diastolic dysfunction within 12 months |
12 months
|
|
Elevation of biomarkers during chemotherapy and up to 12 months of follow-up
Tidsram: 12 months
|
Elevation of biomarkers (NT-pro BNP and troponin) during chemotherapy and up to 24 months of follow-up |
12 months
|
|
Quality of life (EuroQol-5D).
Tidsram: 12 months
|
Quality of life measured by questionnaire in up to 12 months. |
12 months
|
|
Cardiovascular complications in 12 months.
Tidsram: 12 months
|
Cardiovascular complications (death, resuscitated cardiac arrest, myocardial infarction, heart failure and cardiac arrhythmias) in 24 months. |
12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Diagnosis of neoplasia within 12 months.
Tidsram: 12 months
|
Diagnosis of another neoplasia |
12 months
|
|
Progression of oncological disease within 12 months.
Tidsram: 12 months
|
Progression of oncological disease |
12 months
|
|
Tumor recurrence within 12 months.
Tidsram: 12 months.
|
Tumor recurrence |
12 months.
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Renato H D. lopes, MD, PhD, Hospital Sirio-Libanes
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Hjärt-kärlsjukdomar
- Sår och skador
- Patologiska processer
- Hjärtsjukdom
- Kemiskt inducerade störningar
- Läkemedelsrelaterade biverkningar och biverkningar
- Strålningsskador
- Patologiska tillstånd, tecken och symtom
- Neoplasmer
- Kardiotoxicitet
- Organiska kemikalier
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Aminer
- Förenad
- Alkohol
- Propanolaminer
- Aminohalkalkol
- Propanoler
- Heterocykliska föreningar, 3-ring
- Karbasol
- Karvedilol
Andra studie-ID-nummer
- AVAP-NG 989
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .